Remikiren

Jump to: navigation, search
Remikiren
Remikiren svg.png
Clinical data
ATC code
Pharmacokinetic data
Protein binding83%
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC33H50N4O6S
Molar mass630.839 g/mol

WikiDoc Resources for Remikiren

Articles

Most recent articles on Remikiren

Most cited articles on Remikiren

Review articles on Remikiren

Articles on Remikiren in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Remikiren

Images of Remikiren

Photos of Remikiren

Podcasts & MP3s on Remikiren

Videos on Remikiren

Evidence Based Medicine

Cochrane Collaboration on Remikiren

Bandolier on Remikiren

TRIP on Remikiren

Clinical Trials

Ongoing Trials on Remikiren at Clinical Trials.gov

Trial results on Remikiren

Clinical Trials on Remikiren at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Remikiren

NICE Guidance on Remikiren

NHS PRODIGY Guidance

FDA on Remikiren

CDC on Remikiren

Books

Books on Remikiren

News

Remikiren in the news

Be alerted to news on Remikiren

News trends on Remikiren

Commentary

Blogs on Remikiren

Definitions

Definitions of Remikiren

Patient Resources / Community

Patient resources on Remikiren

Discussion groups on Remikiren

Patient Handouts on Remikiren

Directions to Hospitals Treating Remikiren

Risk calculators and risk factors for Remikiren

Healthcare Provider Resources

Symptoms of Remikiren

Causes & Risk Factors for Remikiren

Diagnostic studies for Remikiren

Treatment of Remikiren

Continuing Medical Education (CME)

CME Programs on Remikiren

International

Remikiren en Espanol

Remikiren en Francais

Business

Remikiren in the Marketplace

Patents on Remikiren

Experimental / Informatics

List of terms related to Remikiren

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.[1]

References

  1. Richter WF, Whitby BR, Chou RC (1996). "Distribution of remikiren, a potent orally active inhibitor of human renin, in laboratory animals". Xenobiotica. 26 (3): 243–54. doi:10.3109/00498259609046705. PMID 8730917.

Linked-in.jpg